Related references
Note: Only part of the references are listed.Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU)
M. J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS)
N. A. Butowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
T. F. Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antiangiogenic agents for the treatment of glioblastoma
Elizabeth R. Gerstner et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Synergistic antiglioma activity of radiotherapy and enzastaurin
Ghazaleh Tabatabai et al.
ANNALS OF NEUROLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
Michael A. Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
JR Graff et al.
CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Temozolomide in the treatment of recurrent malignant glioma
SM Chang et al.
CANCER (2004)
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice
KA Keyes et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Current management of glioblastoma multiforme
SA Grossman et al.
SEMINARS IN ONCOLOGY (2004)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide
MA Rosenthal et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2004)
Antiangiogenic effects of a protein kinase C beta-selective small molecule
BA Teicher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN
D Koul et al.
ONCOGENE (2001)
Share Paper
